Sarmad Sadeghi, MD, PhD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089-9172
Phone+1 323 865 0553
ORCID ORCID Icon0000-0003-2654-1991 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Sarmad Sadeghi earned his medical degree at Tehran University of Medical Sciences. He has a Master of Science degree (MS) in Health Information Sciences and a Doctor of Philosophy degree (PhD) in Public Health Management and Policy Sciences from the University of Texas Health Sciences Center at Houston.
    He completed his internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation. He completed his hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. Dr. Sadeghi joined the faculty at the division of oncology of University of Southern California in 2013 and has a clinical and research focus in genitourinary malignancies, specifically bladder, kidney and prostate cancers.
    Dr. Sadeghi is the study chair and principal investigator of a number of multicenter clinical trials and is also an active member of SWOG cooperative group and the California Cancer Consortium.
    Dr. Sadeghi is well published with several original articles and abstracts in peer reviewed journals and international meetings.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. USPSTF Recommendations and Colorectal Cancer in Younger Adults-Current Challenges and Future Opportunities. JAMA Netw Open. 2024 Oct 01; 7(10):e2436305. Sadeghi S, Barzi A. PMID: 39361287.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    2. EphrinB2: Expression of a novel potential target in renal cell carcinoma. Indian J Urol. 2023 Jul-Sep; 39(3):223-227. Gupta C, Sali AP, Jackovich A, Ma B, Sadeghi S, Quinn D, Gill P, Gill I. PMID: 37575160; PMCID: PMC10419785.
      View in: PubMed   Mentions: 1  
    3. The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. Cancers (Basel). 2022 Dec 03; 14(23). Cacciamani GE, Barzi A, Eppler MB, Lara PN, Pan CX, Bhanvadia SK, Gill P, Aron M, Gill I, Sadeghi S. PMID: 36497466; PMCID: PMC9735798.
      View in: PubMed   Mentions: 1  
    4. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 01 20; 41(3):640-650. Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. PMID: 35984996.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    5. Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterol. 2020 11; 7(1). Barzi A, Yang D, Kim AW, Shah MA, Sadeghi S. PMID: 33148789; PMCID: PMC7643494.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. How to optimize cancer therapy when coronavirus hits the fan. Am J Manag Care. 2020 06; 26(5 Spec No.):SP167. Barzi A, Sadeghi S. PMID: 32639133.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    7. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis. Am J Clin Oncol. 2020 06; 43(6):428-434. Jiao X, Hay JW, Sadeghi S, Barzi A. PMID: 32187027; PMCID: PMC9303075.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathol Res Pract. 2020 Jun; 216(6):152967. Gupta C, Sali A, Ma B, Jackovich A, Sadeghi S, Quinn D, Gill P, Gill I. PMID: 32362422; PMCID: PMC9084634.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clin Genitourin Cancer. 2020 10; 18(5):351-360.e3. Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS. PMID: 32146152; PMCID: PMC9135583.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have? Eur Urol Focus. 2020 07 15; 6(4):623-626. Basu A, Sadeghi S. PMID: 31753690.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. PMID: 31398279; PMCID: PMC6941667.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019 10 10; 37(29):2682-2688. Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN. PMID: 31390274; PMCID: PMC7006847.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    13. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432; PMCID: PMC7446934.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    14. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urol Oncol. 2019 01; 37(1):1-11. Bazargani ST, Clifford TG, Djaladat H, Schuckman AK, Wayne K, Miranda G, Cai J, Sadeghi S, Dorff T, Quinn DI, Daneshmand S. PMID: 30470611; PMCID: PMC7474471.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI. PMID: 28749918; PMCID: PMC7523177.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    16. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI. PMID: 28749907; PMCID: PMC7515771.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    17. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 07; 35(7):459.e15-459.e24. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn DI, Sadeghi S. PMID: 28284890; PMCID: PMC8942442.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. PMID: 28117881; PMCID: PMC6879196.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    19. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). Barzi A, Sadeghi S, Kattan MW, Meropol NJ. PMID: 25794514; PMCID: PMC4402362.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsPHPublic Health
    20. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A. PMID: 24188686.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    21. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. Hepgur M, Sadeghi S, Dorff TB, Quinn DI. PMID: 23788831; PMCID: PMC3684142.
      View in: PubMed   Mentions: 8  
    22. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin Oncol. 2012 Oct; 39(5):608-14. Sadeghi S, Garcia JA. PMID: 23040257.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer. 2012 Jul 01; 118(13):3277-82. Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, Rini BI. PMID: 22139966.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. Sadeghi S, Barzi A, Kattan MW, Meropol NJ. PMID: 21372042.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    25. A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. Sadeghi S, Barzi A, Sadeghi N, King B. PMID: 16140572.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    26. Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. Sadeghi S, Barzi A, Smith JW. PMID: 16160263.
      View in: PubMed   Mentions: 1     Fields:    
    27. Mitral valve recurrence of a left atrial myxoma. Eur J Cardiothorac Surg. 2002 Mar; 21(3):568-73. Sadeghi N, Sadeghi S, Karimi A. PMID: 11888789.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Determinants of operative mortality following primary coronary artery bypass surgery. Eur J Cardiothorac Surg. 2002 Feb; 21(2):187-92. Sadeghi N, Sadeghi S, Mood ZA, Karimi A. PMID: 11825722.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    29. Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. Barzi A, Sadeghi S, King BR. PMID: 15458058.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Sarmad's Networks
    Concepts (161)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (19)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.